A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

Summary

This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.

Timeline

Start

2021-04-19

Primary completion

2024-10-20

Completion

2027-04-20

Drugs

Indications